Guselkumab (Tremfya)

Key Messages

• Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
• The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
• This review assesses Guselkumab (Tremfya): 100 mg per 1 mL patient-controlled injector, 100 mg per 1 mL prefilled syringe, 200 mg per 2 mL prefilled syringe, 200 mg per 2 mL prefilled pen administered by subcutaneous injection.
• Guselkumab (Tremfya IV): 200 mg per 20 mL vial administered by IV infusion.
• Indication: For the treatment of adult patients with moderately to severely active Crohn’s disease.